PREZCOBIX PED Drug Patent Profile
When do Prezcobix Ped patents expire, and when can generic versions of Prezcobix Ped launch?
Prezcobix Ped is a drug marketed by Janssen Prods and is included in one NDA.
The generic ingredient in PREZCOBIX PED is cobicistat; darunavir ethanolate. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the cobicistat; darunavir ethanolate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for PREZCOBIX PED?
- What are the global sales for PREZCOBIX PED?
- What is Average Wholesale Price for PREZCOBIX PED?
Summary for PREZCOBIX PED
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 4 |
| DailyMed Link: | PREZCOBIX PED at DailyMed |
Recent Clinical Trials for PREZCOBIX PED
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Janssen Pharmaceutical K.K. | Phase 4 |
| University of Colorado, Denver | Phase 2/Phase 3 |
| Janssen Scientific Affairs, LLC | Phase 2/Phase 3 |
Pharmacology for PREZCOBIX PED
US Patents and Regulatory Information for PREZCOBIX PED
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Prods | PREZCOBIX PED | cobicistat; darunavir ethanolate | TABLET, FOR SUSPENSION;ORAL | 220092-001 | Feb 27, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
